Compare Essex Property Trust, Inc. (ESS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Natera Inc. Common Stock — how do they compare? Essex Property Trust, Inc. trades at $268.84 (market cap $17.47B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.3× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.81% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 112 Days and Natera Inc. Common Stock for 0 Days on average.
| ESS | NTRA | |
|---|---|---|
Market Cap | $17.47B | $57.03B |
Volume | 425,157 | 1,131,157 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $425.64 |
52-Week Low | $239.61 | $179.42 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $24.07B | $56.18B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $269.37, down 0.38% with neutral technical signals. The company shows strong profitability with 67.9% gross margins and 21.48% net income, though recent earnings were mixed with Q2 2026 missing expectations. Revenue growth has been steady, reaching $1.89B in 2025. Analyst consensus is mixed with 38.3% buy ratings and a $300.77 price target, representing 11.7% upside. Recent news highlights strong Q2 results and legal resolution.
ESS offers solid fundamentals with premium valuation (P/E 42.35) and strong operational efficiency. Key risks include earnings volatility and high debt levels ($6.46B long-term). The stock presents opportunity from raised guidance and institutional interest, but requires monitoring of West Coast real estate market conditions and interest rate sensitivity.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
